| pubmed-article:14512873 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14512873 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:14512873 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:14512873 | lifeskim:mentions | umls-concept:C0085295 | lld:lifeskim |
| pubmed-article:14512873 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:14512873 | lifeskim:mentions | umls-concept:C1515999 | lld:lifeskim |
| pubmed-article:14512873 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:14512873 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:14512873 | pubmed:dateCreated | 2003-9-26 | lld:pubmed |
| pubmed-article:14512873 | pubmed:abstractText | An imbalance in Th1 and Th2 cytokine production is implicated in disease progression of HCV. Our aim was to determine the effect of IL-10 administration in patients with HCV-related liver disease. Thirty patients with advanced fibrosis who had failed antiviral therapy were enrolled in a 12-month treatment regimen with SQ IL-10 given daily or thrice weekly. Liver biopsies were performed before and after therapy. Serum and PBMC were collected for HCV RNA, ALT, and functional T-cell analysis. IL-10 led to significant improvement in serum ALT (mean ALT: day 0 = 142 +/- 17 vs. month 12 = 75 +/- 10; P <.05). Hepatic inflammation score decreased by at least 2 in 13 of 28 patients (mean decrease from 4.6 +/- 0.3 to 3.7 +/- 0.3, P <.05) and 11 of 28 showed a reduction in fibrosis score (mean change from 5.0 +/- 0.2 to 4.5 +/- 0.3, P <.05). Serum HCV RNA levels increased by 0.5 log during therapy (mean HCV RNA day 0: 12.3 +/- 3.0 Meq/mL; 12 months: 38 Meq/mL; P <.05) and returned to baseline at the end of follow-up (11.0 +/- 2.4 Meq/mL). Five patients developed viral loads of greater than 120 Meq/mL and two of these developed an acute flare in serum ALT. IL-10 caused a decrease in the number of HCV-specific CD4+ and CD8+ IFN-gamma secreting T cells and alterations in PBMC cytokine production towards a Th2 dominant profile. These changes parallel the improvement in ALT and rise in HCV RNA. In conclusion, long-term rIL-10 therapy appears to decrease disease activity, but also leads to increased HCV viral burden via alterations in immunologic viral surveillance. | lld:pubmed |
| pubmed-article:14512873 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14512873 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14512873 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14512873 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14512873 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14512873 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14512873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14512873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14512873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14512873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14512873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14512873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14512873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14512873 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14512873 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:14512873 | pubmed:issn | 0270-9139 | lld:pubmed |
| pubmed-article:14512873 | pubmed:author | pubmed-author:LiuChenC | lld:pubmed |
| pubmed-article:14512873 | pubmed:author | pubmed-author:NelsonDavid... | lld:pubmed |
| pubmed-article:14512873 | pubmed:author | pubmed-author:DavisGary LGL | lld:pubmed |
| pubmed-article:14512873 | pubmed:author | pubmed-author:Soldevila-Pic... | lld:pubmed |
| pubmed-article:14512873 | pubmed:author | pubmed-author:ZhuHaizhenH | lld:pubmed |
| pubmed-article:14512873 | pubmed:author | pubmed-author:TuZhengkunZ | lld:pubmed |
| pubmed-article:14512873 | pubmed:author | pubmed-author:AbdelmalekMan... | lld:pubmed |
| pubmed-article:14512873 | pubmed:author | pubmed-author:XuYi LingYL | lld:pubmed |
| pubmed-article:14512873 | pubmed:author | pubmed-author:CabreraRoniel... | lld:pubmed |
| pubmed-article:14512873 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14512873 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:14512873 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14512873 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14512873 | pubmed:pagination | 859-68 | lld:pubmed |
| pubmed-article:14512873 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:meshHeading | pubmed-meshheading:14512873... | lld:pubmed |
| pubmed-article:14512873 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14512873 | pubmed:articleTitle | Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. | lld:pubmed |
| pubmed-article:14512873 | pubmed:affiliation | Department of Medicine, University of Florida, 1600 S.W. Archer Road, PO Box 100214, Gainesville, FL 32610-0214, USA. nelsodr@medicine.ufl.edu | lld:pubmed |
| pubmed-article:14512873 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14512873 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:14512873 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:14512873 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:14512873 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14512873 | lld:pubmed |
